
## Dylan L Steen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8322301/publications.pdf Version: 2024-02-01



DVIAN | STEEN

#	Article	IF	CITATIONS
1	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. Journal of Clinical Lipidology, 2016, 10, 472-489.	1.5	219
2	Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research. JAMA Cardiology, 2019, 4, 375.	6.1	43
3	Patterns and predictors of lipidâ€lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large <scp>US</scp> managedâ€care population. Clinical Cardiology, 2017, 40, 155-162.	1.8	41
4	Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open, 2017, 7, e013255.	1.9	32
5	Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239Â234 Patients During 2005 to 2018 in the United States. Journal of the American Heart Association, 2022, 11, e022198.	3.7	26
6	Prognostic Evaluation of Catalytic Iron in Patients With Acute Coronary Syndromes. Clinical Cardiology, 2013, 36, 139-145.	1.8	24
7	Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events. Cardiology and Therapy, 2013, 2, 125-134.	2.6	22
8	Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age. Journal of the American Geriatrics Society, 2016, 64, 1054-1060.	2.6	19
9	Atrial fibrillation decision support tool: Population perspective. American Heart Journal, 2017, 194, 49-60.	2.7	9
10	Lipid-lowering Therapy and Goal Achievement in High-risk Patients From French General Practice. Clinical Therapeutics, 2018, 40, 1484-1495.e22.	2.5	6
11	The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT–TIMI 22. Clinical Cardiology, 2018, 41, 68-73.	1.8	5
12	Design and rationale for the supermarket and web-based intervention targeting nutrition (SuperWIN) for cardiovascular risk reduction trial. American Heart Journal, 2022, 248, 21-34.	2.7	4
13	Statin potency associated with incident diabetes in a real-world evaluation. Evidence-Based Medicine, 2014, 19, 68-68.	0.6	3
14	Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents. Journal of Thrombosis and Thrombolysis, 2016, 41, 285-292.	2.1	2
15	Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins. Reviews in Cardiovascular Medicine, 2012, 13, e48-51.	1.4	1
16	Highlights from the 2017 American Heart Association Scientific Sessions in Anaheim, California. Journal of Thrombosis and Thrombolysis, 2018, 45, 466-468.	2.1	0
17	Highlights from the 2018 American College of Cardiology scientific session in Orlando, Florida. Journal of Thrombosis and Thrombolysis, 2018, 46, 431-433.	2.1	0
18	Highlights from the 2018 European Society of Cardiology Congress in Munich, Germany. Journal of Thrombosis and Thrombolysis, 2019, 47, 312-315.	2.1	0

#	Article	IF	CITATIONS
19	Highlights from the 2019 American College of Cardiology Scientific Sessions in New Orleans, LA. Journal of Thrombosis and Thrombolysis, 2019, 48, 78-80.	2.1	Ο
20	Highlights from the 2018 American Heart Association Scientific Sessions in Chicago, Illinois. Journal of Thrombosis and Thrombolysis, 2019, 47, 596-599.	2.1	0